Aggressive chemo combo with stem cell rescue tested for rare breast cancer

NCT ID NCT00003042

Completed Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tested a very strong chemotherapy regimen followed by a stem cell transplant in 41 people with stage IIIB inflammatory breast cancer. The goal was to see if this intense approach could help keep the cancer from coming back and improve survival. Participants received several chemotherapy drugs, then had their own stem cells returned to help the body recover.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chemotherapy (cisplatin, cyclophosphamide, doxorubicin, melphalan, paclitaxel, tamoxifen) plus stem cell transplant
What this could lead to: If successful, this approach could offer a more aggressive treatment option for inflammatory breast cancer, potentially improving relapse-free and overall survival.
What could go wrong: This is a small, completed phase II trial with only 41 participants, so results may not apply broadly. High-dose chemotherapy carries serious risks like infection, organ damage, and treatment-related death.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm inflammatory breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

City of Hope Comprehensive Cancer Center

Duarte, California, 91010-3000, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.